We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » VaxGen Faces Deadline to Begin Clinical Trial Despite FDA Hold
VaxGen Faces Deadline to Begin Clinical Trial Despite FDA Hold
December 1, 2006
VaxGen said that HHS's Office of Public Health Emergency Preparedness has unilaterally imposed Dec. 18 as the new deadline for the company to begin its next Phase II clinical trial for its next-generation anthrax vaccine, although the FDA put a clinical hold on the trial.